Stocktoria
TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 1951-01-01
TEVA PHARMACEUTICAL INDUSTRIES LTD financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $17.3B | $16.5B | $15.8B | $14.9B | $15.9B |
| Gross profit | $8.9B | $8.1B | $7.6B | $7.0B | $7.6B |
| R&D expense | — | — | — | $98.0M | — |
| Operating income | $2.2B | -$303.0M | $433.0M | -$2.2B | $1.7B |
| Interest expense | $916.0M | $1.0B | $1.0B | $930.0M | $891.0M |
| Income tax | -$180.0M | $676.0M | -$7.0M | -$643.0M | $211.0M |
| Net income | $1.4B | -$1.6B | -$559.0M | -$2.4B | $417.0M |
| EPS (diluted) | $1.21 | $-1.45 | $-0.50 | $-2.20 | $0.38 |
| Operating cash flow | $1.6B | $1.2B | $1.4B | $1.6B | $798.0M |
| Free cash flow | — | — | — | $1.0B | $236.0M |
| Cash & equivalents | $3.6B | $3.3B | $3.2B | $2.8B | $2.2B |
| Inventory | $3.2B | $3.0B | $4.0B | $3.8B | $3.8B |
| Total assets | $40.7B | $39.3B | $43.5B | $44.0B | $47.7B |
| Total liabilities | $32.8B | $33.6B | $35.4B | $35.4B | $36.4B |
| Shareholders' equity | $7.9B | $5.4B | $8.1B | $8.6B | $11.2B |
Source: SEC EDGAR filings · CIK 0000818686 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.